Physician profile
Alla Seraya
NPI 1427084177
$3,504.42
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2020: $322 · 2021: $932 · 2022: $781 · 2023: $955 · 2024: $14.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $969.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $591.87 | 2019-2024 | Ubrelvy, Qulipta, Viberzi |
| Amgen INC. | $305.39 | 2019-2022 | |
| Amarin Pharma, INC. | $291.59 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $282.36 | 2021-2023 | |
| Glaxosmithkline, LLC. | $249.43 | 2019-2023 | Trelegy Ellipta |
| Ironwood Pharmaceuticals, INC | $227.91 | 2020-2023 | Linzess |
| Nestle Healthcare Nutrition INC. | $217.96 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $156.23 | 2021-2023 | Verquvo, Steglatro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.23 | 2019-2022 | |
| Allergan, INC. | $111.44 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $103.82 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $102.14 | 2021-2023 | |
| Lilly USA, LLC | $85.00 | 2020-2023 | Jardiance, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $80.52 | 2022-2023 | Breztri, Farxiga |
| Paratek Pharmaceuticals, INC. | $80.04 | 2023 | Nuzyra |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $73.72 | 2021-2023 | Seglentis, Livalo |
| Sunovion Pharmaceuticals INC. | $63.18 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $40.48 | 2023 | Quviviq |
| Novo Nordisk INC | $39.22 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $38.29 | 2020-2021 | |
| Pfizer INC. | $37.93 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $35.71 | 2023 | Gemtesa |
| Nevro Corp. | $34.21 | 2022 | |
| Genentech USA, INC. | $23.65 | 2019 | |
| Dova Pharmaceuticals | $22.79 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $21.17 | 2023 | Inpefa |
| Ibsa Pharma INC. | $19.18 | 2021 | |
| Arbor Pharmaceuticals, INC. | $18.80 | 2020 | |
| Hikma Pharmaceuticals USA | $17.62 | 2019 | |
| Nabriva Therapeutics, Plc | $16.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alla Seraya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.